GlassScriptPhysician profile
Dennis Thomas Cozzens
NPI 1952470676
$6,939.50
in general payments reported to CMS, 2019-2025
22 companies · $554 in 2025
The $554 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $610 · 2020: $206 · 2021: $905 · 2022: $1,574 · 2023: $1,641 · 2024: $1,450 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,598 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,598.10 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,048.96 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,037.58 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $791.18 | 2021-2025 | Caplyta |
| Lundbeck LLC | $567.74 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $543.42 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $526.44 | 2021-2024 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $465.98 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $410.86 | 2021-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $286.47 | 2022-2023 | Aristada, Lybalvi, Vivitrol |
| Corium, LLC | $241.72 | 2022-2024 | Azstarys, Azstarys |
| Axsome Therapeutics, INC. | $229.93 | 2023-2025 | Auvelity, Sunosi |
| Tris Pharma INC | $184.52 | 2022-2025 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $179.11 | 2019-2022 | |
| Allergan, INC. | $142.59 | 2019 | |
| Almatica Pharma LLC | $72.38 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $42.31 | 2023-2024 | Quviviq |
| Avanir Pharmaceuticals, INC. | $40.39 | 2022 | |
| Ironshore Pharmaceuticals INC. | $36.48 | 2021-2023 | Jornay Pm |
| Eisai INC. | $35.93 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $28.04 | 2024 | Invega Sustenna |
| Neuronetics, INC. | $15.25 | 2025 | Neurostar Tms Therapy System |
| Shire North American Group INC | $12.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Cozzens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.